Research Progress in Fractional Exhaled Nitric Oxide and Asthma-chronic Obstructive Pulmonary Disease Overlap Syndrome

doi:10.12114/j.issn.1007-9572.2018.00.416

Abstract

Abstract: Asthma-chronic obstructive pulmonary disease overlap（ACO） is a group of clinical syndromes characterized by asthma and chronic obstructive pulmonary disease.ACO leads to lower quality of life because of its frequent acute exacerbation.The pathogenesis of ACO is unknown，but in essence，it is still a chronic airway inflammatory disease.Fractional exhaled nitric oxide（FeNO） is a new noninvasive airway inflammation detection technique developed in recent years.It is widely used in asthma research because it is closely related to eosinophilic airway inflammation.It is noteworthy that in recent years，FeNO has been found to be associated with the chronic airway inflammation in ACO.The eosinophilic airway inflammation is also associated with the response to inhaled corticosteroids therapy，suggesting that FeNO may be a potential biomarker for monitoring the level of airway inflammation in ACO patients.In this paper，the research progress of the relationship between FeNO and ACO is reviewed.

Key words: Asthma；Pulmonary disease, chronic obstructive；Nitric oxide

摘要： 支气管哮喘-慢性阻塞性肺疾病重叠（ACO）是一组兼具支气管哮喘及慢性阻塞性肺疾病特征的临床综合征，其更易发生急性加重而导致患者生活质量下降。ACO发病机制不明，但其本质仍是一种慢性气道炎症性疾病。呼出气一氧化氮（FeNO）是近年来发展起来的一项新的无创气道炎症检测技术，因其与嗜酸粒细胞气道炎症密切相关而广泛用于支气管哮喘研究。值得关注的是，近年研究发现，FeNO与ACO患者的慢性气道炎症相关。由于嗜酸粒细胞气道炎症与吸入激素治疗的反应性相关，提示FeNO可能是一种监测ACO患者气道炎症水平的潜在生物标志物。本文就FeNO与ACO关系的研究进展做一综述，以期为临床医生对ACO的诊断提供借鉴。

关键词: 哮喘；肺疾病, 慢性阻塞性；一氧化氮

SUN Jian,SHEN Juxin. Research Progress in Fractional Exhaled Nitric Oxide and Asthma-chronic Obstructive Pulmonary Disease Overlap Syndrome　[J]. Chinese General Practice, 2019, 22(15): 1879-1883. DOI: 10.12114/j.issn.1007-9572.2018.00.416.
孙健,沈巨信. 呼出气一氧化氮与支气管哮喘-慢性阻塞性肺疾病重叠关系的研究进展[J]. 中国全科医学, 2019, 22(15): 1879-1883. DOI: 10.12114/j.issn.1007-9572.2018.00.416.

References

［1］BATEMAN E D，REDDEL H K，VAN ZYL-SMIT R N，et al．The asthma-COPD overlap syndrome：towards a revised taxonomy of chronic airways diseases?［J］．Lancet Respir Med，2015，3（9）：719-728．DOI：10.1016/S2213-2600（15）00254-4.
［2］MENEZES A M B，MONTES DE OCA M，PéREZ-PADILLA R，
et al．Increased risk of exacerbation and hospitalization in subjects with an overlap phenotype：COPD-asthma［J］．Chest，2014，145（2）：297-304．DOI：10.1378/chest.13-0622.
［3］SHAYA F T，DONGYI D，AKAZAWA M O，et al．Burden of concomitant asthma and COPD in a Medicaid population［J］．Chest，2008，134：14-19．DOI：10.1378/chest.07-2317.
［4］MIRAVITLLES M，SORIANO J B，ANCOCHEA J，et al．Characterisation of the overlap COPD-asthma phenotype.Focus on physical activity and health status［J］．Respir Med，2013，107（7）：1053-1060．DOI：10.1016/j.rmed.2013.03.007.
［5］KARRASCH S，LINDE K，RüCKER G，et al．Accuracy of FENO for diagnosing asthma：a systematic review［J］．Thorax，2017，72（2）：109-116．DOI：10.1136/thoraxjnl-2016-208704.
［6］李娜嘉，林江涛.呼出气一氧化氮检测在呼吸道疾病诊治中的应用进展［J］．中华医学杂志，2014，94（42）：3354-3356．DOI：10.3760/CMA.J.ISSN.0376-2491.2014.42.018.
LI N J，LIN J T.Application progress of fractional exhaled nitric oxide detection in diagnosis and treatment of respiratory diseases［J］．Natl Med J Chin，2014，94（42）：3354-3356．DOI：10.3760/CMA.J.ISSN.0376-2491.2014.42.018.
［7］DONOHUE J F，HERJE N，CRATER G，et al．Characterization of airway inflammation in patients with COPD using fractional exhaled nitric oxide levels：a pilot study［J］．Int J Chron Obstruct Pulmon Dis，2014，9：745-751．DOI：10.2147/COPD.S44552.
［8］ALCáZAR-NAVARRETE B，ROMERO-PALACIOS P J，RUIZ-SANCHO A，et al．Diagnostic performance of the measurement of nitric oxide in exhaled air in the diagnosis of COPD phenotypes［J］．Nitric Oxide，2016，54：67-72．DOI：10.1016/j.niox.2016.02.003.
［9］KOBAYASHI S，HANAGAMA M，YAMANDA S，et al．Inflammatory biomarkers in asthma-COPD overlap syndrome［J］．Int J Chron Obstruct Pulmon Dis，2016，11：2117-2123．DOI：10.2147/COPD.S113647.
［10］CHEN F J，HUANG X Y，LIU Y L，et al．Importance of fractional exhaled nitric oxide in the differentiation of asthma-COPD overlap syndrome，asthma，and COPD［J］．Int J Chron Obstruct Pulmon Dis，2016，11：2385-2390．DOI：10.2147/COPD.S115378.
［11］Global Initiative for Asthma.Global Strategy for Asthma Management and Prevention（2015 update）［EB/OL］．［2018-06-11］．https：//www.ginasthma.org.
［12］Global Initiative for Asthma.Global Strategy for Asthma Management and Prevention（2017 update）［EB/OL］．［2018-06-11］．https：//www.ginasthma.org.
［13］SIN D D，MIRAVITLLES M，MANNINO D M，et al．What is asthma-COPD overlap syndrome? Towards a consensus definition from a round table discussion［J］．Eur Respir J，2016，48（3）：664-673．DOI：10.1183/13993003.00436-2016.
［14］MIRAVITLLES M，SOLER-CATALUFIA J J，CALLE M，et al．A new approach to grading and treating COPD based on clinical phenotypes：summary of the Spanish COPD guidelines（GesEPOC）［J］．Prim Care Respir J，2013，22（1）：117-121．DOI：10.4104/pcrj.2013.00016.
［15］MIRAVITLLES M，SOLER-CATALU?A J J，CALLE M，et al．Spanish guidelines for management of chronic obstructive pulmonary disease（GesEPOC） 2017.Pharmacological treatment of stable phase［J］．Arch Bronconeumol，2017，53（6）：324-335．DOI：10.1016/j.arbres.2017.03.018.
［16］BENFANTE A，SORINO C，SCICHILONE N.The asthma-COPD overlap syndrome（ACOS）：hype or reality? That is，a curiosity for the media or an opportunity for physicians？［J］．Shortness of Breath，2014，3（4）：165-174.
［17］ZEKI A A，SCHIVO M，CHAN A，et al．The asthma-COPD overlap syndrome：a common clinical problem in the elderly［J］．J Allergy（Cairo），2011，2011：861926．DOI：10.1155/2011/861926.
［18］COSIO B G，SORIANO J B，LóPEZ-CAMPOS J L，et al．Defining the asthma-COPD overlap syndrome in a COPD cohort［J］．Chest，2016，149（1）：45-52．DOI：10.1378/chest.15-1055.
［19］GIBSON P G，MCDONALD V M.Asthma-COPD overlap 2015：now we are six［J］．Thorax，2015，70（7）：683-691．DOI：10.1136/thoraxjnl-2014-206740.
［20］MATSUMOTO K，SEKIA N，FUKUYAMA S.Prevalence of asthma with airflow limitation，COPD，and COPD with variable airflow limitation in older subjects in a general Japanese population：the Hisayama Study［J］．Respir Investig，2015，53（1）：22-29．DOI：10.1016/j.resinv.2014.08.002.
［21］HARADA T，YAMASAKI A，FUKUSHIMA T，et al．Causes of death in patients with asthma and asthma-chronic obstructive pulmonary disease overlap syndrome［J］．Int J Chron Obstruct Pulmon Dis，2015，10：595-602．DOI：10.2147/COPD.S77491.
［22］ALSHABANAT A，ZAFARI Z，ALBANYAN O，et al．Asthma and COPD Overlap Syndrome（ACOS）：a systematic review and meta analysis［J］．PLoS One，2015，10（9）：e0136065．DOI：10.1371/journal.pone.0136065.
［23］SORINO C，PEDONE C，SCICHILONE N.Fifteen-year mortality of patients with asthma-COPD overlap syndrome［J］．Eur J Intern Med，2016，34：72-77．DOI：10.1016/j.ejim.2016.06.020.
［24］DE MARCO R，PESCE G，MARCON A，et al．The coexistence of asthma and chronic obstructive pulmonary disease（COPD）：prevalence and risk factors in young，middle-aged and elderly people from the general population［J］．PLoS One，2013，8（5）：e62985．DOI：10.1371/journal.pone.0062985.
［25］GIBSON P G，SIMPSON J L.The overlap syndrome of asthma and COPD：what are its features and how important is it?［J］．Thorax，2009，64（8）：728-735．DOI：10.1136/thx.2008.108027.
［26］HUANG S，VASQUEZ M M，HALONEN M，et al．Asthma，airflow limitation and mortality risk in the general population［J］．Eur Respir J，2015，45（2）：338-346．DOI：10.1183/09031936.00108514.
［27］YAMAUCHI Y，YASUNAGA H，MATSUI H，et al．Comparison of in-hospital mortality in patients with COPD，asthma and asthma-COPD overlap exacerbations［J］．Respirology，2015，20（6）：940-946．DOI：10.1111/resp.12556.
［28］BAI J W，MAO B，YANG W L，et al．Asthma-COPD overlap syndrome showed more exacerbations however lower mortality than COPD［J］．QJM，2017，110（7）：431-436．DOI：10.1093/qjmed/hcx005.
［29］MALERBA M，RADAELI A，OLIVINI A，et al．Exhaled nitric oxide as a biomarker in COPD and related comorbidities［J］．Biomed Res Int，2014，2014：271918．DOI：10.1155/2014/271918.
［30］HATZIAGOROU E，TSANAKAS J.Assessment of airway inflammation with exhaled NO measurement［J］．Hippokratia，2007，11（2）：51-62.
［31］DWEIK R A，BOGGS P B，ERZURUM S C，et al．An official ATS clinical practice guideline：interpretation of exhaled nitric oxide levels（FENO） for clinical applications［J］．Am J Respir Crit Care Med，2011，184（5）：602-615．DOI：10.1164/rccm.9120-11ST.
［32］BARNES P J，DWEIK R A，GELB A F，et al．Exhaled nitric oxide in pulmonary diseases：a comprehensive review［J］．Chest，2010，138（3）：682-692．DOI：10.1378/chest.09-2090.
［33］BASTAIN T M，ISLAM T，BERHANE K T，et al．Exhaled nitric oxide，susceptibility and new-onset asthma in the Children's Health Study［J］．Eur Respir J，2011，37（3）：523-531．DOI：10.1183/09031936.00021210.
［34］SOTER S，BARTA I，ANTUS B.Predicting sputum eosinophilia in exacerbations of COPD using exhaled nitric oxide［J］．Inflammation，2013，36（5）：1178-1185．DOI：10.1007/s10753-013-9653-8.
［35］RICCIARDOLO F L，SORBELLO V，CIPRANDI G.FeNO as biomarker for asthma phenotyping and management［J］．Allergy Asthma Proc，2015，36（1）：e1-8．DOI：10.2500/aap.2015.36.3805.
［36］MALINOVSCHI A，LUDVIKSDOTTIR D，TUFVESSON E，et al．
Application of nitric oxide measurements in clinical conditions beyond asthma［J］．Eur Clin Respir J，2015，2：28517．DOI：10.3402/ecrj.v2.28517.
［37］KALININA E P，DENISENKO Y K，VITKINA T I，et al．The mechanisms of the regulation of immune response in patients with comorbidity of chronic obstructive pulmonary disease and asthma［J］．Can Respir J，2016，2016：4503267．DOI：10.1155/2016/4503267.
［38］邓玎玎，周爱媛，双庆翠，等．呼出气一氧化氮测定对支气管哮喘-慢性阻塞性肺疾病重叠综合征的诊断价值［J］．中华结核和呼吸杂志，2017，40（2）：98-101．DOI：10.3760/cma.j.issn.1001-0939.2017.02.004.
DENG D D，ZHOU A Y，SHUANG Q C，et al．The value of fractionated exhaled nitric oxide in the diagnosis of asthma-chronic obstructive pulmonary disease overlap syndrome［J］．Chinese Journal of Tuberculosis and Respiratory Diseases，2017，40（2）：98-101．DOI：10.3760/cma.j.issn.1001-0939.2017.02.004.
［39］TAMADA T，SUGIURA H，TAKAHASHI T，et al．Biomarker-based detection of asthma-COPD overlap syndrome in COPD populations［J］．Int J Chron Obstruct Pulmon Dis，2015，10（1）：2169-2176．DOI：10.2147/COPD.S88274.
［40］WOODRUFF P G，VAN DEN BERGE M，BOUCHER R C，et al．
American Thoracic Society/National Heart，Lung，and Blood Institute Asthma-Chronic Obstructive Pulmonary Disease Overlap Workshop Report［J］．Am J Respir Crit Care Med，2017，196（3）：375-381．DOI：10.1164/rccm.201705-0973WS.
［41］ISHIURA Y，FUJIMURA M，SHIBA Y，et al．A comparison of the efficacy of once-daily fluticasone furoate/vilanterole with twice-daily fluticasone propionate/salmeterol in asthma-COPD overlap syndrome［J］．Pulm Pharmacol Ther，2015，35：28-33．DOI：10.1016/j.pupt.2015.10.005.
［42］FENG J X，LIN Y，LIN J，et al．Relationship between fractional exhaled nitric oxide level and efficacy of inhaled corticosteroid in asthma-COPD overlap syndrome patients with different disease severity［J］．J Korean Med Sci，2017，32（3）：439-447．DOI：10.3346/jkms.2017.32.3.439.
［43］陈琼琰，戴元荣，金晨慈，等．酮替芬治疗不同呼出气一氧化氮水平的哮喘-慢性阻塞性肺疾病重叠综合征的临床疗效研究［J］．中国全科医学，2018，21（3）：278-282.DOI：10.3969/j.issn.1007-9572.2017.00.172.
CHEN Q Y，DAI Y R，JIN C C，et al．Clinical efficacy of ketotifen for the treatment of Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome in patients with different exhaled nitric oxide levels［J］．Chinese General Practice，2018，21（3）：278-282.DOI：10.3969/j.issn.1007-9572.2017.00.172.
［44］KONDO M，TAMAOKI J.Therapeutic approaches of asthma and COPD overlap［J］．Allergol Int，2018，67（2）：187-190．DOI：10.1016/j.alit.2017.09.002.
［45］GAO J，IWAMOTO H，KOSKELA J，et al．Characterization of sputum biomarkers for asthma-COPD overlap syndrome［J］．Int J Chron Obstruct Pulmon Dis，2016，11：2457-2465．DOI：10.2147/COPD.S113484.
［46］CARPAGNANO G E，LACEDONIA D，CARONE M，et al．Study of mitochondrial DNA alteration in the exhaled breath condensate of patients affected by obstructive lung diseases［J］．J Breath Res，2016，10（2）：026005．DOI：10.1088/1752-7155/10/2/026005.
［47］中国医师协会呼吸医师分会.无创气道炎症评估支气管哮喘的临床应用中国专家共识［J］．中华结核和呼吸杂志，2015，38（5）：329-341．DOI：10.3760/cma.j.issn.1001-0939.2015.05.004.
Chinese Association of Chest Physicians.Chinese expert consensus on clinical use of non-invasive airway inflammation assessment in bronchial asthma［J］．Chin J Tuberc Respir Dis，2015，38（5）：329-341．DOI：10.3760/cma.j.issn.1001-0939.2015.05.004.